Abu Dhabi Health and Eli Lilly Partner to Use AI in Developing Obesity and Alzheimer's Treatments
Collaboration Overview
Abu Dhabi Health has announced a partnership with Eli Lilly, one of the world's leading pharmaceutical companies, to develop treatments for obesity and Alzheimer's disease using artificial intelligence technology.
Research Focus
The collaboration aims to accelerate drug discovery and development processes by utilizing AI to analyze complex biological data, identify potential therapeutic targets, and optimize treatment candidates for both conditions.
Obesity and Alzheimer's represent significant global health challenges. Obesity affects millions worldwide and is linked to numerous comorbidities, while Alzheimer's disease remains one of the most prevalent forms of dementia with limited treatment options currently available.
AI in Drug Development
Artificial intelligence offers promising capabilities in pharmaceutical research, including the ability to process vast amounts of medical data, predict drug interactions, and potentially reduce the time and cost associated with bringing new treatments to market.
This partnership reflects a growing trend in the pharmaceutical industry to incorporate machine learning and AI technologies into traditional drug development pipelines.